Stage-specific outcomes of patients with Uterine leiomyosarcoma: A comparison of the international federation of gynecology and obstetrics and american joint committee on cancer staging systems

Journal of Clinical Oncology

Volumn 27, Issue 12, 2009, Pages 2066-2072

  Hensley, Martee L ^b   Zivanovic, Oliver ^a   Leitao, Mario M ^b   Iasonos, Alexia ^b   Jacks, Lindsay M ^b   Zhou, Qin ^b   Abu Rustum, Nadeem R ^b   Soslow, Robert A ^b   Juretzka, Margrit M ^a   Chi, Dennis S ^a   Barakat, Richard R ^b   Brennan, Murray F ^a  

^a Gynecology Service

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GYNECOLOGY; HEALTH CARE ORGANIZATION; HUMAN; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; OBSTETRICS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; UTERUS CANCER; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INTERNATIONAL AGENCIES; LEIOMYOSARCOMA; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 65349159791     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.8366     Document Type: Article

References (39)

1. Harlow BL, Weiss NS, Lofton S: The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 76:399-402, 1986
2. Echt G, Jepson J, Steel J, et al: Treatment of uterine sarcomas. Cancer 66:35-39, 1990
3. Berchuck A, Rubin SC, Hoskins WJ, et al: Treatment of uterine leiomyosarcoma. Obstet Gynecol 71:845-850, 1988
4. Major FJ, Blessing JA, Silverberg SG, et al: Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71: 1702-1709, 1993 (suppl 4)
5. Hannigan EV, Gomez LG: Uterine leiomyosarcoma. Am J Obstet Gynecol 134:557-564, 1979
6. Mayerhofer K, Obermair A, Windbichler G, et al: Leiomyosarcoma of the uterus: A clinicopathologic multicenter study of 71 cases. Gynecol Oncol 74:196-201, 1999
7. Peters WA 3rd, Howard DR, Andersen WA, et al: Uterine smooth-muscle tumors of uncertain malignant potential. Obstet Gynecol 83:1015-1020, 1994
8. Dinh TA, Oliva EA, Fuller AF Jr, et al: The treatment of uterine leiomyosarcoma: Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 92:648-652, 2004
9. Nordal RR, Kristensen GB, Kaern J, et al: The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol 34:797-802, 1995
10. Omura GA, Blessing JA, Major F, et al: A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: A Gynecologic Oncology Group study. J Clin Oncol 3:1240-1245, 1985
11. Rose PG, Boutselis JG, Sachs L: Adjuvant therapy for stage I uterine sarcoma. Am J Obstet Gynecol 156:660-662, 1987
12. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al: Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89:460-469, 2003
13. Gadducci A, Landoni F, Sartori E, et al: Uterine leiomyosarcoma: Analysis of treatment failures and survival. Gynecol Oncol 62:25-32, 1996
14. Sorbe B, Johansson B: Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas. Int J Oncol 32:1111-1117, 2008
15. Reed NS, Mangioni C, Malmström H, et al: Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer 44:808-818, 2008
16. Hensley ML, Maki R, Venkatraman E, et al: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 20:2824-2831, 2002
17. Pautier P, Genestie C, Rey A, et al: Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88:1425- 1431, 2000
18. Kapp DS, Shin JY, Chan JK: Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: Emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112:820-830, 2008
19. Hajdu SI, Shiu MH, Brennan MF: The role of the pathologist in the management of soft tissue sarcomas. World J Surg 12:326-331, 1988
20. Bell SW, Kempson RL, Hendrickson MR: Problematic uterine smooth muscle neoplasms: A clinicopathologic study of 213 cases. Am J Surg Pathol 18:535-558, 1994
21. Ben-Porat L, Panageas KS, Hanlon C, et al: Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma. Cancer 106: 163-171, 2006
22. Goenen M, Heller G: Concordance probability and discriminatory power in proportional hazards regression. Biometrika 92:965-970, 2005
23. Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312:1604-1608, 1985
24. Leitao MM, Sonoda Y, Brennan MF, et al: Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 91: 209-212, 2003
25. Goff BA, Rice LW, Fleischhacker D, et al: Uterine leiomyosarcoma and endometrial stromal sarcoma: Lymph node metastases and sites of recurrence. Gynecol Oncol 50:105-109, 1993
26. Soslow RA: Uterine mesenchymal tumors: A review of selected topics. Diagn Histopathol 4:175- 188, 2008
27. Royston P, Sauerbrei W: A new measure of prognostic separation in survival data. Stat Med 23:723-748, 2004
28. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996
29. Graf E, Schmoor C, Sauerbrei W, et al: Assessment and comparison of prognostic classification schemes for survival data. Stat Med 18:2529-2545, 1999
30. Kattan MW, Leung DH, Brennan MF: Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 20:791-796, 2002
31. Wierda WG, O'Brien S, Wang X, et al: Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109:4679-4685, 2007
32. Bochner BH, Kattan MW, Vora KC: Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24:3967-3972, 2006
33. Karakiewicz PI, Briganti A, Chun FK, et al: Multi-institutional validation of a new renal cancerspecific survival nomogram. J Clin Oncol 25:1316- 1322, 2007
34. Walz J, Gallina A, Saad F, et al: A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 25:3576-3581, 2007
35. Abu-Rustum NR, Iasonos A, Zhou Q, et al: Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am J Obstet Gynecol 198:457.e1-457.e5, 2008
36. Gimotty PA, Guerry D, Ming ME, et al: Thin primary cutaneous malignant melanoma: A prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 22:3668-3676, 2004
37. Guerriere MR, Detsky AS: Neural networks: What are they? Ann Intern Med 115:906-907, 1991
38. Sternberg CN: Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol 24:3819-3820, 2006
39. Kattan MW: Nomograms are superior to staging and risk grouping systems for identifying highrisk patients: Preoperative application in prostate cancer. Curr Opin Urol 13:111-116, 2003